The vaccine against Norovirus – the agent that causes vomiting and diarrhea, will be tested in phase three at 27 British medical facilities, starting at the end of October.
The study focused on people aged 60 and older because they are more susceptible to the virus. About 2,500 patients will participate, be randomly injected with placebo or vaccine, and then followed for 25 months. In addition to the UK, the trial will take place in five other countries, including Japan, Canada, and Australia, recruiting a total of 25,000 volunteers.
Theo GuardianModerna Group presides over vaccine research and development, hoping for a minimum protection effectiveness of 65%. The unit also needs to check whether the vaccine is suitable for seasonal use, similar to the flu shot.
If successful, Moderna will apply for vaccine licensing in 2026. The approval process is expected to take a year. During this time, the vaccine continues to be tested in adolescents and young children.
The injection is prepared with mRNA technology similar to the Covid-19 vaccine, which will guide the body to create immunity to pathogens and fight against future viruses. Previously, the vaccine went through two stages of clinical trials, showing its ability to create a strong immune response in humans.
Theo BBCNorovirus is difficult to identify, changing genotype over time. The vaccine contains the three most common virus strains to achieve high disease prevention effectiveness.
In the UK, Norovirus has a major impact, causing nearly 4 million infections each year, 12,000 hospital admissions and 80 deaths. Groups at high risk of contracting the virus include the elderly, medical staff, babysitters, flight attendants, employees and tourists.
The virus is contagious and causes vomiting and diarrhea, so it is also called “stomach flu”. Most people will recover in 1-3 days, but they can still spread the virus. People under 5 years old, elderly or immunocompromised are at increased risk of severe infection. In addition, when not properly cared for, the disease can cause severe dehydration leading to death.
Currently, the world does not have an approved Norovirus vaccine, and there is no specific treatment medicine. People with mild illness should rehydrate with over-the-counter solutions, sports drinks, and beverages that do not contain alcohol or caffeine. Hospitalized patients receive intravenous fluid care until recovery.
To prevent Norovirus infection, experts recommend washing hands regularly, thoroughly cooking shellfish foods, and washing fruits and vegetables; clean and disinfect surfaces that may harbor pathogens; wash clothes with hot water. Patients should stay at home for two days after symptoms stop.